

**CAUSES, TYPES, SYMPTOMS AND DIAGNOSIS OF METHYL
MELONIC ACIDEMIA (MMA), COMMON SYMPTOMS OF
METHYL MALONIC ACID (MMA) AND HOMOCYSTEINE
(HMA -HCY0, DIFFERENTIAL DIAGNOSIS OF METHYL
MALONIC ACIDEMIA (MMA), TREATMENT OF METHYL
MELONYL ACIDEMIA**

**Vinayasree. C¹ , Mohan naidu.K² , Muralinath. E² , Amrutham Sandeep³,
Venkat Naveen. A², Guruprasad.M⁴ , Sravani pragna.K²**

¹College of Veterinary Science, Korutla, PVRNTVU, Telengana, India

²College of veterinary science, Proddatur, Andhra Pradesh, India

³Indian Veterinary Research Institute (IVRI), Izathnagar 243122 Barielly district, Utter Pradesh, India

⁴Vaishnavi microbial Pvt. Ltd. Hyderabad. India.

Corresponding Author Mail: muralinathennamuri@gmail.com

Abstract:

Methylmalonic acidemia (MMA) is a rare inherited metabolic disorder manifested by impaired metabolism of certain amino acids and fatty acids. It occurs by a deficiency of the enzyme methylmalonyl-CoA mutase, which leads to the collection of toxic levels of methylmalonic acid in the body. This article gives an overall idea about methylmalonic acidemia, along with its symptoms, causes, diagnosis, and treatment options. It also intensifies the importance of early detection and management in improving outcomes for individuals affected by this condition.

Keywords:

Methyl malonyl-CoA mutase, methyl melonic acid, metabolic disorders, propionate, genetic disorder, inborn error of metabolism, adenosylcobalamin, poor feeding as well as growth, dehydration, lethargy, vomiting, low muscle tone, intellectual disability, seizures and anemia, homocystinuria, methionine, cystathionine betasynthase, crawling, walking, low gain weight, low growth, cognitive impairment, nearsightedness, dislocated lenses, optic nerve damage, skeletal disorders namely tall stature, long limbs, more risk of bone fractures and stroke, other vascular problems, propionic acidemia, propionyl - CoA carboxylase, metabolic acidosis, neurological symptoms, methionine, argino succinic aciduria, ammonia, glutaric acidemia, vitamin B12, carnitine and betaine.

Introduction:

Methylmalonic acidemia (MMA) is a rare inherited metabolic disorder manifested by the collection of methylmalonic acid (MMA) in the body. It happens by a deficiency in the enzyme methylmalonyl-CoA mutase (MUT), which plays a critical role in the catabolism of certain amino acids and fatty acids. This article gives an overall idea about the depths of methylmalonic

acidemia, exploring its causes, symptoms, diagnosis, treatment options, and ongoing research efforts.

Causes and Types of MMA:

Methylmalonic acidemia happens primarily by mutations in the MUT gene, which encodes the enzyme methylmalonyl-CoA mutase. MUT mutations result in the occurrence of disturbance in normal functioning of the enzyme, leading to the impaired catabolism of propionate, an essential amino acid and precursor for various biological processes. Consequently, elevated levels of MMA and other toxic metabolites collect in the body, leading to the characteristic symptoms of MMA.

There are several sub types of MMA, including:

Isolated Methylmalonic Acidemia (MMA):

This is the most common form of MMA, manifested by a deficiency in the MUT enzyme. Isolated methylmalonic acidemia (MMA) is a rare genetic disorder that influences the body's capability to process certain proteins and fats in a proper manner. It is categorized as an inborn error of metabolism and is usually affected by mutations in the genes participated in the metabolism of a compound termed as methylmalonic acid.

Generally, the body breaks down proteins and fats from the food we eat into usable forms. In individuals with isolated methylmalonic acidemia, there is a deficiency of an enzyme known as methylmalonyl-CoA mutase or a defect in the metabolism of its co factor, adenosylcobalamin (a form of vitamin B12). As a result, methylmalonic acid and its byproducts retain in the blood and tissues, result in a wide range of symptoms.

The symptoms of isolated methylmalonic acidemia can vary widely in their severity and presentation. Common symptoms include poor feeding and growth, vomiting, dehydration, lethargy, low muscle tone (hypotonia), developmental delays, intellectual disability, seizures, and anemia. If left untreated, the condition can cause life-threatening complications.

Methylmalonic Acidemia with Homocystinuria (MMA-HCY):

Methylmalonic acidemia with homocystinuria (MMA-HCY) is a rare genetic disorder that influences the body's capability to break down certain proteins and fats. It is an inherited metabolic disorder happened by mutations in genes that are participated in the metabolism of the amino acids methionine and homocysteine.

In individuals with MMA-HCY, there is a deficiency of enzymes known as methyl malonyl-CoA mutase and cystathionine beta-synthase. These enzymes play a major role in changing certain amino acids and fats into other substances that the body can use for energy production and other essential functions.

The deficiency of functional enzymes leads to the collection of toxic substances in the body, primarily methylmalonic acid and homocysteine. Enhanced levels of these substances can cause a wide range of symptoms and complications.

Common symptoms of MMA-HCY may include:

Developmental delays: Infants with MMA-HCY may feel delays in reaching developmental milestones namely sitting, crawling, and walking.

Failure to thrive: Children with MMA-HCY often can not gain weight as well as growth at a normal rate.

Intellectual disability: Some individuals with MMA-HCY may experience intellectual disability or cognitive impairment.

Seizures: Seizures can occur in individuals with MMA-HCY.

Vision problems: Eye-related symptoms namely nearsightedness, dislocated lenses, and optic nerve damage, may happen in some cases.

Bone abnormalities: Homocystinuria lead to the occurrence of skeletal abnormalities, such as tall stature, long limbs, and an enhanced risk of bone fractures.

Blood clotting issues: Homocystinuria result in an enhanced tendency for blood clot formation, which can enhance the risk of stroke or other vascular problems.

Clinical Presentation and Symptoms:

The symptoms of MMA can evident shortly after birth or later in infancy and vary in severity. Common signs and symptoms include:

Failure to thrive: Infants with MMA often have difficulty gaining weight and may experience poor growth.

Developmental delays: Children with MMA may experience delays in attaining developmental milestones namely sitting, crawling, and walking.

Metabolic crises: Periodic metabolic crises, triggered by infections, stress, or dietary changes, can result in vomiting, dehydration, lethargy, and even life-threatening complications.

Neurological manifestations: MMA can influence the central nervous system, leading to symptoms namely seizures, intellectual disability, muscle weakness, and involuntary movements.

Diagnosis:

Diagnosing MMA involves a combination of clinical evaluation, biochemical testing, and genetic analysis. Enhanced levels of methylmalonic acid in blood and urine samples, coupled with abnormal organic acid profiles, provide initial information about the disorder. Genetic testing is responsible for confirming the diagnosis and identifying specific mutations in the MUT gene.

Differential diagnosis of MMA:

Methylmalonic acidemia (MMA) is a group of inherited metabolic disorders manifested by the body's insufficiency to process certain proteins and fats in a proper manner. It results in the buildup of a toxic substance termed as methylmalonic acid in the blood and tissues. The symptoms and severity of MMA can vary widely based on the specific type and the age of onset. Here are some differential diagnoses to consider when evaluating a patient with suspected MMA:

1. Propionic Acidemia (PA):

This is another organic acidemia that presents with symptoms similar to MMA. It is happened by a deficiency of the enzyme propionyl-CoA carboxylase. Both MMA and PA can result in metabolic acidosis, developmental delay, feeding difficulties and neurological symptoms.

2. Isolated Methylmalonic Aciduria (IMMA):

IMMA is related to a form of MMA where only the methylmalonic acid pathway is affected. It occurs by a deficiency of the enzyme methylmalonyl-CoA mutase. IMMA typically presents in infancy or early childhood with metabolic acidosis, failure to thrive, vomiting, and lethargy.

3. Vitamin B12 Deficiency:

MMA can also be secondary to vitamin B12 deficiency, either due to incomplete dietary intake or imperfect absorption. Vitamin B12 is a co factor enforced for the function of methylmalonyl-CoA mutase. A thorough evaluation of vitamin B12 levels and intrinsic factor antibodies play a major role in differentiating between primary MMA and vitamin B12 deficiency.

4. Homocystinuria:

Homocystinuria is an inherited disorder manifested by the impaired metabolism of the amino acid methionine. It can present with similar symptoms to MMA, including developmental delay, intellectual disability, visual problems, and skeletal abnormalities. Differentiating between MMA and homocystinuria may need specific metabolic testing namely measuring homocysteine levels.

5. Urea Cycle Disorders:

Some urea cycle disorders, such as argininosuccinic aciduria, can contribute with metabolic acidosis and neurological symptoms similar to MMA. These disorders result from deficiencies in enzymes participated in the metabolism of ammonia. Ammonia levels and specific amino acid profiles can assist in comparing between MMA and urea cycle disorders.

6. Organic Acidemias:

Other organic acidemias, namely glutaric acidemia type 1 and isovaleric acidemia, can present with metabolic acidosis, neurological symptoms, and developmental delay. These disorders are characterized by specific enzyme deficiencies leading to the accumulation of specific organic acids.

Treatment Options:

Managing MMA requires a multidisciplinary approach, involving medical professionals specializing in genetics, metabolism, nutrition, and supportive care. Treatment options include:

Dietary interventions: Individuals with MMA may require a specialized low-protein diet supplemented with essential amino acids and certain forms of vitamin B12. Dietary management aims to limit the intake of precursor amino acids that contribute to the production of toxic metabolites.

Medications: Some medications, such as carnitine and betaine, may be prescribed to help improve metabolism and reduce toxic metabolite levels.

Emergency protocols: It is crucial to establish emergency protocols for metabolic crises to promptly address life-threatening situations.

Liver or combined liver-kidney transplantation: In severe cases of MMA, where dietary and medical management fail, liver or combined liver-kidney transplantation may be considered as a treatment option.

Ongoing Research and Future Perspectives:

Research efforts are ongoing to develop more effective treatments for MMA. Promising areas of investigation include gene therapy, enzyme replacement therapy, and the use of small molecules to modulate metabolic pathways. These emerging therapies hold the potential to address the underlying metabolic defects in MMA, providing hope for improved outcomes and quality of life for affected individuals.

Conclusion:

Methylmalonic acidemia is a complex and challenging inherited metabolic disorder that can have profound effects on affected individuals. Early diagnosis, appropriate medical interventions, and ongoing care are crucial to managing the condition and mitigating its associated complications. Continued research and advancements in treatment modalities offer hope for improved outcomes and a better understanding of this rare disorder, paving the way for enhanced support and interventions for individuals with methylmalonic acidemia and their families.

References & Further Reading

- Coelho D, Suormala T, Stucki M, Lerner-Ellis JP, Rosenblatt DS, Newbold RF, Baumgartner MR, Fowler B. Gene identification for the cblD defect of vitamin B12 metabolism. *N Engl J Med.* 2008 Apr 3;358(14):1454-64. doi: 10.1056/NEJMoa072200. Citation on PubMed
- Deodato F, Boenzi S, Santorelli FM, Dionisi-Vici C. Methylmalonic and propionic aciduria. *Am J Med Genet C Semin Med Genet.* 2006 May 15;142C(2):104-12. doi: 10.1002/ajmg.c.30090. Citation on PubMed
- Fowler B, Leonard JV, Baumgartner MR. Causes of and diagnostic approach to methylmalonic acidurias. *J Inherit Metab Dis.* 2008 Jun;31(3):350-60. doi: 10.1007/s10545-008-0839-4. Epub 2008 Jun 19. Citation on PubMed
- Horster F, Baumgartner MR, Viardot C, Suormala T, Burgard P, Fowler B, Hoffmann GF, Garbade SF, Kolker S, Baumgartner ER. Long-term outcome in methylmalonic acidurias is influenced by the underlying defect (mut0, mut-, cblA, cblB). *Pediatr Res.* 2007 Aug;62(2):225-30. doi: 10.1203/PDR.0b013e3180a0325f. Citation on PubMed

- Horster F, Hoffmann GF. Pathophysiology, diagnosis, and treatment of methylmalonic aciduria-recent advances and new challenges. *Pediatr Nephrol.* 2004 Oct;19(10):1071-4. doi: 10.1007/s00467-004-1572-3. Epub 2004 Aug 4. Citation on PubMed
- Manoli I, Sloan JL, Venditti CP. Isolated Methylmalonic Acidemia. 2005 Aug 16 [updated 2022 Sep 8]. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. *GeneReviews(R)* [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2023. Available from

<http://www.ncbi.nlm.nih.gov/books/NBK1231/> Citation on PubMed
- Miousse IR, Watkins D, Coelho D, Rupar T, Crombez EA, Vilain E, Bernstein JA, Cowan T, Lee-Messer C, Enns GM, Fowler B, Rosenblatt DS. Clinical and molecular heterogeneity in patients with the cblD inborn error of cobalamin metabolism. *J Pediatr.* 2009 Apr;154(4):551-6. doi: 10.1016/j.jpeds.2008.10.043. Epub 2008 Dec 5. Citation on PubMed
- Ogier de Baulny H, Saudubray JM. Branched-chain organic acidurias. *Semin Neonatol.* 2002 Feb;7(1):65-74. doi: 10.1053/siny.2001.0087. Citation on PubMed
- Tanpaiboon P. Methylmalonic acidemia (MMA). *Mol Genet Metab.* 2005 May;85(1):2-6. doi: 10.1016/j.ymgme.2005.03.008. No abstract available. Citation on PubMed